Marieke E Straver

Summary

Affiliation: The Netherlands Cancer Institute
Country: The Netherlands

Publications

  1. ncbi Accurate axillary lymph node dissection is feasible after neoadjuvant chemotherapy
    Marieke E Straver
    Department of Surgery, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Am J Surg 198:46-50. 2009
  2. ncbi The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
    Marieke E Straver
    Department of Surgical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res Treat 119:551-8. 2010
  3. ncbi Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer
    M E Straver
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands
    Eur J Cancer 45:2284-92. 2009
  4. ncbi Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial
    Marieke E Straver
    Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Ann Surg Oncol 17:1854-61. 2010
  5. ncbi The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy
    M E Straver
    Department of Surgical Oncology, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Ann Surg Oncol 17:2411-8. 2010
  6. ncbi Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer
    Marieke E Straver
    The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands
    J Clin Oncol 28:731-7. 2010
  7. ncbi Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response
    Jorma J de Ronde
    Department of Bioinformatics and Statistics, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Breast Cancer Res Treat 119:119-26. 2010
  8. ncbi Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer
    Tjeerd S Aukema
    Department of Nuclear Medicine, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Eur J Cancer 46:3205-10. 2010
  9. ncbi MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy
    Marieke E Straver
    Department of Surgical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Ann Surg 251:701-7. 2010
  10. ncbi Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype
    Claudette E Loo
    Department of Radiology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital NKI AVL, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    J Clin Oncol 29:660-6. 2011

Detail Information

Publications11

  1. ncbi Accurate axillary lymph node dissection is feasible after neoadjuvant chemotherapy
    Marieke E Straver
    Department of Surgery, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Am J Surg 198:46-50. 2009
    ..Recently, lower axillary lymph node retrieval after neoadjuvant chemotherapy was reported. We did not have this experience, and retrospectively analyzed our axillary lymph node dissections (ALNDs)...
  2. ncbi The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
    Marieke E Straver
    Department of Surgical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res Treat 119:551-8. 2010
    ..023). A pCR is unlikely to be achieved in tumors that have a good prognosis-signature. Tumors with a poor prognosis-signature are more sensitive to chemotherapy...
  3. ncbi Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer
    M E Straver
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands
    Eur J Cancer 45:2284-92. 2009
    ..The purpose of this study is to analyse nodal staging and axillary response in breast cancer patients treated with neoadjuvant chemotherapy (NAC) to explore venues to safely spare patients axillary clearance whenever it could be avoided...
  4. ncbi Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial
    Marieke E Straver
    Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Ann Surg Oncol 17:1854-61. 2010
    ..The aim of the current substudy was to evaluate the identification rate and the nodal involvement...
  5. ncbi The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy
    M E Straver
    Department of Surgical Oncology, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Ann Surg Oncol 17:2411-8. 2010
    ..The aim of this study was to assess the differences between histological and receptor-based subtypes in breast-conserving surgery and pathological complete response (pCR) after neoadjuvant chemotherapy...
  6. ncbi Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer
    Marieke E Straver
    The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands
    J Clin Oncol 28:731-7. 2010
    ..CONCLUSION Absence of knowledge regarding the extent of nodal involvement in the ART arm appears to have no major impact on the administration of adjuvant therapy...
  7. ncbi Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response
    Jorma J de Ronde
    Department of Bioinformatics and Statistics, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Breast Cancer Res Treat 119:119-26. 2010
    ..For Luminal(IHC) and triple negative(IHC) tumors, further subdivision into molecular subgroups does not offer a clear advantage in treatment selection...
  8. ncbi Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer
    Tjeerd S Aukema
    Department of Nuclear Medicine, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Eur J Cancer 46:3205-10. 2010
    ..The aim of this prospective study was to assess the incidence of extra-axillary lymph node involvement on baseline FDG PET/CT in patients with stage II-III breast cancer scheduled for neo-adjuvant chemotherapy...
  9. ncbi MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy
    Marieke E Straver
    Department of Surgical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Ann Surg 251:701-7. 2010
    ..The aim of this study was to establish an magnetic resonance imaging (MRI)-based interpretation model to facilitate the selection of breast-conserving surgery (BCS) after neoadjuvant chemotherapy (NAC)...
  10. ncbi Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype
    Claudette E Loo
    Department of Radiology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital NKI AVL, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    J Clin Oncol 29:660-6. 2011
    ..To evaluate the relevance of breast cancer subtypes for magnetic resonance imaging (MRI) markers for monitoring of therapy response during neoadjuvant chemotherapy (NAC)...
  11. ncbi Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients
    Marieke E Straver
    Department of Surgical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 37:1069-76. 2010
    ....